Compugen Ltd. (CGEN) Upgraded to Buy by Zacks Investment Research
Zacks Investment Research upgraded shares of Compugen Ltd. (NASDAQ:CGEN) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning. They currently have $7.00 price objective on the stock.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
Separately, FBR & Co restated a buy rating on shares of Compugen in a report on Wednesday, June 22nd. Six equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and an average price target of $10.40.
Shares of Compugen (NASDAQ:CGEN) traded up 0.97% on Tuesday, reaching $6.25. 39,953 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $6.82 and a 200-day moving average price of $6.66. Compugen has a 12-month low of $4.32 and a 12-month high of $7.79. The company’s market cap is $318.18 million.
Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.04. Compugen had a negative net margin of 245.83% and a negative return on equity of 26.46%. Equities research analysts anticipate that Compugen will post ($0.56) EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC raised its position in shares of Compugen by 0.8% in the second quarter. ProShare Advisors LLC now owns 37,652 shares of the company’s stock valued at $244,000 after buying an additional 300 shares during the last quarter. Vident Investment Advisory LLC acquired a new position in Compugen during the second quarter worth about $522,000. Janney Montgomery Scott LLC raised its position in Compugen by 2.2% in the second quarter. Janney Montgomery Scott LLC now owns 45,787 shares of the company’s stock worth $293,000 after buying an additional 1,000 shares in the last quarter. Vanguard Group Inc. raised its position in Compugen by 12.4% in the second quarter. Vanguard Group Inc. now owns 740,047 shares of the company’s stock worth $4,796,000 after buying an additional 81,729 shares in the last quarter. Finally, Rothschild Investment Corp IL raised its position in Compugen by 2.2% in the second quarter. Rothschild Investment Corp IL now owns 458,510 shares of the company’s stock worth $2,971,000 after buying an additional 10,000 shares in the last quarter. 14.09% of the stock is owned by hedge funds and other institutional investors.
Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.
Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.